First, trial inclusion criteria based solely on cognitive impairment and biomarkers for amyloid-β and tau may still select for a hugely heterogeneous population, even if these biomarkers ensure that 100% of the trial participants go on to develop substantial amyloid-β and tau neuropathology by death. This evidence concerns the gene MAPT and Cognitive impairment.